---
title: "Crinetics Pharmaceuticals, Inc. (CRNX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CRNX.US.md"
symbol: "CRNX.US"
name: "Crinetics Pharmaceuticals, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-20T06:41:08.873Z"
locales:
  - [en](https://longbridge.com/en/quote/CRNX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CRNX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CRNX.US.md)
---

# Crinetics Pharmaceuticals, Inc. (CRNX.US)

## Company Overview

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing’s disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves’ disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.crinetics.com](https://www.crinetics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:16.000Z

**Overall: C (0.49)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 57 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 2277.50% |  |
| Net Profit YoY | -51.22% |  |
| P/B Ratio | 2.88 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3684080867.52 |  |
| Revenue | 18069000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -39.17% | E |
| Profit Margin | -2747.18% | E |
| Gross Margin | -834.24% | E |
| Revenue YoY | 2277.50% | A |
| Net Profit YoY | -51.22% | D |
| Total Assets YoY | 2.94% | C |
| Net Assets YoY | 2.12% | C |
| Cash Flow Margin | 83.44% | C |
| OCF YoY | 2277.50% | A |
| Turnover | 0.01 | E |
| Gearing Ratio | 8.61% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Crinetics Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "2277.50%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-51.22%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.88",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "3684080867.52",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "18069000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-39.17%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-2747.18%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-834.24%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "2277.50%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-51.22%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "2.94%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "2.12%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "83.44%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "2277.50%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.01",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "8.61%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -7.42 | 174/190 | - | - | - |
| PB | 2.88 | 111/190 | 4.21 | 3.61 | 2.39 |
| PS (TTM) | 203.89 | 154/190 | 3636.27 | 2877.37 | 553.46 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **16**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 12 | 75% |
| Overweight | 3 | 19% |
| Hold | 1 | 6% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 34.94 |
| Highest Target | 97.00 |
| Lowest Target | 55.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CRNX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CRNX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CRNX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CRNX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**